Nordic Nanovector – Approved prospectus
Reference is made to the press release dated 18 June 2014, regarding the successful closing of a NOK 250 million private placement, and the minutes from the extraordinary general meeting held on 27 June 2014, where it was resolved to carry out a subsequent repair issue.
The Norwegian Financial Supervisory Authority (Nw. Finanstilsynet) has approved the prospectus of the Nordic Nanovector dated 28 August 2014, (the "Prospectus"), for the offering of up to 2,000,000 subsequent offering shares with subscription rights for eligible shareholders as of 27 June 2014 at a subscription price of NOK 25 per subsequent offering share. The subscription period in the subsequent offering will commence on 1 September 2014 and expire at 16:00 hours CET on 12 September 2014.
The Prospectus will be published on 29 August 2014 and will be available at the following websites: www.abgsc.com and www.dnb.no/emisjoner. Hard copies of the Prospectus may be obtained by contacting Nordic Nanovector (+47 22 18 33 01), ABG Sundal Collier Norge (+47 22 01 60 00) or DNB Markets (+47 23 26 81 01).
ABG Sundal Collier and DNB Markets are acting as managers for the subsequent repair issue.
For further information, please refer to the Prospectus.
Jan A. Alfheim, CEO
Phone: ( 47) 22 18 33 01
Cell: ( 47) 46 44 00 45
Fax: ( 47) 22 58 00 07
E-mail: jaa@nordicnanovector.no
Tone Kvåle, CFO
Phone: ( 47) 22 18 33 01
Cell: ( 47) 91 51 95 76
Fax: ( 47) 22 58 00 07
E-mail: tkv@nordicnanovector.no
About Nordic Nanovector AS
Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other hematological malignancies.
About Betalutin
Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).
Tags:
